New gene therapy boost immune system to cure cancer

December 15, 2002

Using a novel gene therapy approach that boosts the body's immune system, a Northwestern University researcher has cured cancer in laboratory mice.

In experiments reported in the Dec. 15 issue of Cancer Research, Chung Lee and colleagues at the Feinberg School of Medicine at Northwestern University applied the gene therapy technique to render immune cells insensitive to transforming growth factor beta (TGF-beta), a powerful, naturally occurring substance in the body called an immunosuppressor that enables cancer cells to evade surveillance by the immune system.

The approach boosted the mice's immune system, which virtually eliminated cancerous tumors in the animals' lungs and prostate gland. "We hypothesized that an immunotherapy strategy that specifically blocks TGF-beta signaling in immune cells, regardless of tumor location or tumor microenvironment, could be highly successful in mediating an antitumor response," said Lee.

Lee is John T. Grayhack, M.D., Professor of Urology at the Feinberg School. Collaborating with Lee and his research group were investigators from the National Cancer Institute, Massachusetts Institute of Technology, the Mayo Clinic and Baylor College of Medicine.

After inserting a mutated gene for the TGF-beta receptor into bone marrow cells, transplanting the cells into mice and subsequently injecting the mice with melanoma cells, the researchers found that 70 percent of the animals survived and showed a virtual absence of metastatic (widely spread) lesions in the lung.

In another group of mice with the mutated TGF-beta gene that were later injected with prostate cancer cells, the gene-targeted approach resulted in 80 percent survival.

All of the control mice in the melanoma and prostate cancer arms of the study that had not received the gene therapy died of metastatic cancer.

Tests showed that in the mice treated with the mutated TGF-beta receptor gene, infection-fighting immune cells had mounted a powerful response to kill cancerous tumors.

Results of the group's studies strongly indicate that a gene therapy approach to inducing TGF-beta insensitivity in transplanted bone marrow cells may be a potent anticancer therapy.

"Our observation in these mice provides a testimony to this possibility," Lee said.

In earlier research studies, Lee and colleagues removed TGF-beta from the prostate cancer of rats. Tumors of half of the animals were eradicated.

While Lee cautions that these results are very preliminary, he also believes that they are extremely encouraging. "We will conduct a few more experiments to further verify these results. It is our hope that we will aggressively pursue a phase I/II clinical trial with cancer patients," Lee said.

"It is possible we may offer mankind an opportunity to eradicate cancer in the future," he said.
-end-
Lee's co-authors in this study were Ali H. Shah, William B. Tabayoyong, Shilajit D. Kundu and Victoria Liu, department of urology, Feinberg School of Medicine; Seong-Jin Kim, National Cancer Institute, Bethesda, Md.; Luk Van Parijs, Massachusetts Institute of Technology, Cambridge, Mass.; Eugene Kwon, Mayo Clinic, Rochester, Minn.; and Norman M. Greenberg, Baylor College of Medicine, Houston.

KEYWORDS: cancer, gene therapy, TGF-beta, bone marrow transplantation

Northwestern University

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.